Bleb vessel density as a predictive factor for surgical revisions after Preserflo Microshunt implantation
Acta Ophthalmologica · 2024
DOI: 10.1111/aos.16642 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Ophthalmologica, 2024. Verfasst von Sophie Schneider und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Optometry, Kepler University Hospital, Johannes Kepler University, Linz, Austria. Hauptthemen laut MEDLINE: Intraocular Pressure, Reoperation, Tomography, Optical Coherence. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Santen.
Abstract (Originalsprache)
Purpose
Bleb failure is a common complication after glaucoma filtration surgery. Different bleb classification schemes incorporating filtration bleb vascularization have been proposed, but the reported correlation with intraocular pressure (IOP) has been variable, possibly because of subjective vascularization grading. The purpose of the present study was to evaluate bleb vascularization after Preserflo Microshunt (PM) implantation using anterior segment OCT‐angiography (AS‐OCTA) as a biomarker for bleb failure.
Methods
Twenty‐three eyes of twenty‐three patients underwent PM implantation. Up to 12 months after surgery PM scleral passage‐centred AS‐OCTA measurements (PLEX Elite 9000) for bleb‐vessel density (BVD) determination were performed and IOP as well as necessity for surgical revisions (needling and open revision) were documented. After multi‐step image analysis (region of interest definition, artefact removal, binarization, BVD calculation), the predictive value of early postoperative BVD for surgical revisions was assessed using logistic regression modelling.
Results
Baseline IOP (23.57 ± 7.75 mmHg) decreased significantly to 8.30 ± 2.12, 9.17 ± 2.33 and 11.70 ± 4.40 mmHg after 1, 2 and 4 week(s), and 13.48 ± 5.83, 11.87 ± 4.49, 12.30 ± 6.65, 11.87 ± 3.11 and 13.05 ± 4.12 mmHg after 2, 3, 6, 9 and 12 month(s), respectively ( p < 0.001). Nine patients (39%) needed surgical revisions after a median time of 2 months. Bleb vessel densities at 2 and 4 weeks were significantly associated with future surgical revisions upon logistic regression analysis (2 W/4 W likelihood‐ratio test p ‐value: 0.0244/0.0098; 2 W/4 W area under the receiver operating characteristics curve: 0.796/0.909).
Conclusion
Filtration bleb vessel density can be determined using AS‐OCTA in the early postoperative period and is predictive for bleb failure after PM implantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Optometry, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
- Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria.
- Hamilton Glaucoma Center, The Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California, San Diego, California, USA.
ORCID-Profile: Sophie Schneider, Anna-Sophie Reisinger
Förderung
- Santen
Zitieren
APA
Schneider, S., Kallab, M., Murauer, O., Reisinger, A. S., Strohmaier, S., Huang, A. S., Bolz, M., & Strohmaier, C. A. (2024). Bleb vessel density as a predictive factor for surgical revisions after Preserflo Microshunt implantation. Acta Ophthalmologica. https://doi.org/10.1111/aos.16642
Vancouver
Schneider S, Kallab M, Murauer O, Reisinger AS, Strohmaier S, Huang AS, et al. Bleb vessel density as a predictive factor for surgical revisions after Preserflo Microshunt implantation. Acta Ophthalmologica. 2024. doi:10.1111/aos.16642
BibTeX
@article{Schneider2024,
author = {Schneider, Sophie and Kallab, Martin and Murauer, Olivia and Reisinger, Anna-Sophie and Strohmaier, Susanne and Huang, Alex S and Bolz, Matthias and Strohmaier, Clemens A},
title = {Bleb vessel density as a predictive factor for surgical revisions after Preserflo Microshunt implantation},
journal = {Acta Ophthalmologica},
year = {2024},
doi = {10.1111/aos.16642}
}
EUVIMED